Recent Posts
- Exxel Pharma Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference
- Exxel Pharma’s Innovative Small Molecule, EX937, Rapidly Advancing Toward First-In-Human Study for the Treatment of Refractory Chronic Cough
- Exxel Pharma to Participate in a “New to Virtual Investor” Segment
- Exxel Pharma to Participate in the Virtual Investor Lunch Break: The Exxel Opportunity
- Exxel Pharma Provides Business Overview and Upcoming Milestones
Recent Comments
No comments to show.